New York, Jan 19, 2026, 14:58 (EST) — Market closed
- Shares of Philip Morris closed Friday at $173.62, rising 0.6%.
- U.S. markets remain closed Monday in observance of Martin Luther King Jr. Day; normal trading kicks off again Tuesday.
- FDA advisers are set to review ZYN modified-risk claims on Jan. 22; PMI will release its results on Feb. 6.
Philip Morris International Inc shares closed Friday at $173.62, rising $1.06, having fluctuated between $170.76 and $174.24 on roughly 5.1 million shares traded. According to the NYSE holiday calendar, U.S. markets will be closed Monday for Martin Luther King Jr. Day. (New York Stock Exchange)
Since there’s no U.S. cash trading on Monday, the real test for PM stock comes when markets reopen Tuesday. The week also features two key moments for the company’s smoke-free strategy: a U.S. regulatory review of its ZYN nicotine pouches and the release of Philip Morris’ quarterly earnings.
Risk sentiment shifted despite the holiday lull. Global equities dipped while safe-haven assets gained ground after U.S. President Donald Trump threatened new tariffs on European countries. Economists pointed to rising policy uncertainty as the trigger. “There is obviously a response (in financial markets) to the new tariff threats,” said George Lagarias, chief economist at Forvis Mazars. (Reuters)
Philip Morris, headquartered in Stamford, Connecticut, markets cigarettes alongside smoke-free options like IQOS heated tobacco devices and ZYN nicotine pouches through Swedish Match. (Reuters)
On Jan. 22, the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee will hold a virtual meeting from 9 a.m. to 4:30 p.m. ET. The agenda includes reviewing Swedish Match’s applications for “modified risk tobacco product” orders for several ZYN pouch flavors. Modified-risk designation is key since it expands what marketing claims a company can make, though the committee’s advice is only advisory. (U.S. Food and Drug Administration)
The FDA has greenlit 20 ZYN nicotine pouch products for sale in the U.S. through its premarket review, but the modified-risk application is a separate hurdle. According to the agency’s ZYN MRTP page, public comments tied to the Jan. 22 meeting must be submitted by 11:59 p.m. ET on Jan. 21. (U.S. Food and Drug Administration)
Philip Morris plans to release its full-year and fourth-quarter 2025 results on Feb. 6 at 9 a.m. EST, per its investor-relations calendar. Investors will be focused on any new details about pricing strategies, cost trends, and how quickly the smoke-free segment is expanding as 2026 approaches. (Philip Morris International)
Philip Morris has a separate countdown on its balance sheet. A December filing revealed the company secured a new $2.0 billion senior unsecured revolving credit facility set to kick in on Jan. 29, replacing an older one. The funds are intended for general corporate use.
That said, risks remain. Regulators might clamp down further on nicotine products, and if advisory committees push back or February demand falls short, Philip Morris’s timeline for moving beyond cigarettes could shift sharply.
PM is set to resume live trading on Tuesday. Key upcoming events include the FDA’s review of ZYN modified-risk applications on Jan. 22, followed by the company’s earnings report and outlook on Feb. 6.
